StageZero Life Sciences Ltd.
SZLSF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | 28.1% | -24.9% | -30.3% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $1 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -13.9% | 2% | 54.1% | 22.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $1 | $1 |
| SG&A Expenses | $0 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $1 | $1 | $1 |
| Operating Income | -$0 | -$1 | -$0 | -$1 |
| % Margin | -70.5% | -178.2% | -60.6% | -102% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$1 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$0 | -$1 |
| % Margin | -79.9% | -166.5% | -74% | -110.2% |
| EPS | -0.003 | -0.005 | -0.003 | -0.007 |
| % Growth | 37.7% | -71% | 53.7% | – |
| EPS Diluted | -0.003 | -0.005 | -0.003 | -0.007 |
| Weighted Avg Shares Out | 124 | 124 | 124 | 124 |
| Weighted Avg Shares Out Dil | 124 | 124 | 124 | 124 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$0 | -$1 |
| % Margin | -67.4% | -141.7% | -62.7% | -100.2% |